187 related articles for article (PubMed ID: 32163214)
1. Clinicopathological characteristics and prognostic factors for canine multicentric non-indolent T-cell lymphoma: 107 cases.
Purzycka K; Peters LM; Desmas I; Davies O; Chang YM; Lara-Garcia A
Vet Comp Oncol; 2020 Dec; 18(4):656-663. PubMed ID: 32163214
[TBL] [Abstract][Full Text] [Related]
2. Prognostic indicators for naïve canine non-indolent T-cell lymphoma treated with combination lomustine, vincristine, procarbazine and prednisolone chemotherapy.
Blaxill J; Buzzacott P; Finlay J
Vet Comp Oncol; 2022 Mar; 20(1):215-226. PubMed ID: 34464024
[TBL] [Abstract][Full Text] [Related]
3. Treatment of canine non-indolent T cell lymphoma using the VELCAP-TSC protocol: A retrospective evaluation of 70 dogs (2003-2013).
Goodman IH; Moore AS; Frimberger AE
Vet J; 2016 May; 211():39-44. PubMed ID: 27017053
[TBL] [Abstract][Full Text] [Related]
4. Treatment of T cell lymphoma in dogs.
Moore AS
Vet Rec; 2016 Sep; 179(11):277. PubMed ID: 27634860
[TBL] [Abstract][Full Text] [Related]
5. Canine T cell lymphoma treated with lomustine, vincristine, procarbazine, and prednisolone chemotherapy in 35 dogs.
Morgan E; O'Connell K; Thomson M; Griffin A
Vet Comp Oncol; 2018 Dec; 16(4):622-629. PubMed ID: 30117253
[TBL] [Abstract][Full Text] [Related]
6. Flow cytometric characterization and clinical outcome of CD4+ T-cell lymphoma in dogs: 67 cases.
Avery PR; Burton J; Bromberek JL; Seelig DM; Elmslie R; Correa S; Ehrhart EJ; Morley PS; Avery AC
J Vet Intern Med; 2014; 28(2):538-46. PubMed ID: 24495161
[TBL] [Abstract][Full Text] [Related]
7. Expression of Apoptosis-regulating Proteins Bcl-2 and Bax in Lymph Node Aspirates from Dogs with Lymphoma.
Meichner K; Fogle JE; English L; Suter SE
J Vet Intern Med; 2016 May; 30(3):819-26. PubMed ID: 27013187
[TBL] [Abstract][Full Text] [Related]
8. Clinical features of canine nodal T-cell lymphomas classified as CD8+ or CD4-CD8- by flow cytometry.
Harris LJ; Rout ED; Labadie JD; Avery PR; Fernandez M; Yoshimoto J; Avery AC
Vet Comp Oncol; 2020 Sep; 18(3):416-427. PubMed ID: 31951040
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of clinical presentation, induction and rescue treatment in 42 cases of canine centroblastic diffuse large B-cell multicentric lymphoma in the United Kingdom.
Davies O; Szladovits B; Polton G; Garden OA; Leo C; Lara-Garcia A
Vet Comp Oncol; 2018 Jun; 16(2):276-287. PubMed ID: 29271043
[TBL] [Abstract][Full Text] [Related]
10. LOPP chemotherapy as a first-line treatment for dogs with T-cell lymphoma.
Brown PM; Tzannes S; Nguyen S; White J; Langova V
Vet Comp Oncol; 2018 Mar; 16(1):108-113. PubMed ID: 28508557
[TBL] [Abstract][Full Text] [Related]
11. CHOP chemotherapy for the treatment of canine multicentric T-cell lymphoma.
Rebhun RB; Kent MS; Borrofka SA; Frazier S; Skorupski K; Rodriguez CO
Vet Comp Oncol; 2011 Mar; 9(1):38-44. PubMed ID: 21303452
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of a 12-week combination chemotherapy followed by lomustine consolidation treatment in canine B- and T-cell lymphoma.
Limmer S; Nerschbach V; Eberle N; Teske E; Simon Betz D
Acta Vet Scand; 2022 Dec; 64(1):36. PubMed ID: 36503518
[TBL] [Abstract][Full Text] [Related]
13. A Retrospective Study of Multi-agent Chemotherapy including either Cyclophosphamide or Lomustine as Initial Therapy for Canine High-grade T-cell Lymphoma (2011-2017).
Elliott J; Baines S
Aust Vet J; 2019 Sep; 97(9):308-315. PubMed ID: 31328256
[TBL] [Abstract][Full Text] [Related]
14. Specific immunotypes of canine T cell lymphoma are associated with different outcomes.
Deravi N; Berke O; Woods JP; Bienzle D
Vet Immunol Immunopathol; 2017 Sep; 191():5-13. PubMed ID: 28895866
[TBL] [Abstract][Full Text] [Related]
15. Lomustine and prednisone as a first-line treatment for dogs with multicentric lymphoma: 17 cases (2004-2005).
Sauerbrey ML; Mullins MN; Bannink EO; Van Dorp TE; Kaneene JB; Obradovich JE
J Am Vet Med Assoc; 2007 Jun; 230(12):1866-9. PubMed ID: 17571992
[TBL] [Abstract][Full Text] [Related]
16. Survival times in dogs with presumptive intracranial gliomas treated with oral lomustine: A comparative retrospective study (2008-2017).
Moirano SJ; Dewey CW; Wright KZ; Cohen PW
Vet Comp Oncol; 2018 Dec; 16(4):459-466. PubMed ID: 29797768
[TBL] [Abstract][Full Text] [Related]
17. Canine indolent and aggressive lymphoma: clinical spectrum with histologic correlation.
Aresu L; Martini V; Rossi F; Vignoli M; Sampaolo M; Aricò A; Laganga P; Pierini A; Frayssinet P; Mantovani R; Marconato L
Vet Comp Oncol; 2015 Dec; 13(4):348-62. PubMed ID: 23782432
[TBL] [Abstract][Full Text] [Related]
18. Response of canine cutaneous epitheliotropic lymphoma to lomustine (CCNU): a retrospective study of 46 cases (1999-2004).
Risbon RE; de Lorimier LP; Skorupski K; Burgess KE; Bergman PJ; Carreras J; Hahn K; Leblanc A; Turek M; Impellizeri J; Fred R; Wojcieszyn JW; Drobatz K; Clifford CA
J Vet Intern Med; 2006; 20(6):1389-97. PubMed ID: 17186855
[TBL] [Abstract][Full Text] [Related]
19. Retrospective analysis for treatment of naïve canine multicentric lymphoma with a 15-week, maintenance-free CHOP protocol.
Curran K; Thamm DH
Vet Comp Oncol; 2016 Aug; 14 Suppl 1():147-55. PubMed ID: 26279153
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of combination chemotherapy for treatment of gastrointestinal lymphoma in dogs.
Rassnick KM; Moore AS; Collister KE; Northrup NC; Kristal O; Chretin JD; Bailey DB
J Vet Intern Med; 2009; 23(2):317-22. PubMed ID: 19192147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
